Symkevi/Kalydeco cleared for use in young CF patients
The combination is the first available to treat the underlying cause of CF in this patient group.
Read More
Tag: Kalydeco
Vertex signs ‘landmark’ deal with NHS for CF therapy
CF patients in England will be among the first in Europe to benefit from access to Kaftrio, if the medicine is approved by the EC
Read More
EU expands scope of Vertex’ Kalydeco
Children with cystic fibrosis as young as six months with certain mutations can now access the treatment
Read More
Campaigners call for NHS access to Orkambi as MP inquiry gets underway
Patients and campaigners took to the streets in London yesterday demanding NHS access to Vertex’ cystic fibrosis drugs, following a public hearing on the situation ordered by MPs.
Read More
Vertex’ three-drug CF combo hits PhIII targets
Vertex’ three-drug cystic fibrosis regimen – combining the investigational next-generation corrector VX-445 with Kalydeco (ivacaftor) and tezacaftor – has achieved primary endpoints of two Phase III studies in patients the condition.
Read More
Kalydeco approved by EU for CF in 12-24 month olds
Vertex Pharmaceuticals says the European Commission has granted approval of the label extension for Kalydeco, to include the treatment of patients with cystic fibrosis (CF) aged 12 to 24 months.
Read More
EU approves Vertex’ cystic fibrosis combo
The European Commission has approved Vertex’ Symveki in a combination regimen with Kalydeco to treat certain patients with cystic fibrosis (CF).
Read More
FDA allows use of Vertex’ Kalydeco in children aged under two
Use of Vertex Pharmaceuticals’ cystic fibrosis drug Kalydeco has been expanded in the US to include some children under the age of two.
Read More
Vertex mulls over NHS England’s offer for CF drugs
Vertex Pharmaceuticals is considering a final offer from NHS England on funding for its cystic fibrosis therapies, but said it remains concerned that the deal on the table does not fully reflect the value of its existing and future medicines for the condition.
Read More
Vertex presents real-world data highlighting benefit of CF drug Kalydeco
Vertex has presented long-term, observational data highlighting the benefit of Kalydeco in patients with cystic fibrosis.
Read More
Vertex offers ‘portfolio approach’ to secure access to CF meds
Vertex has presented NHS England with an “innovative long-term framework proposal” that hopes to secure access for all eligible patients to its current and future portfolio of cystic fibrosis (CF) medicines.
Read More
SMC welcomes Jevtana but turns four others away
Patients in Scotland with advanced prostate cancer will be able to get routine access to Sanofi Genzyme’s Jevtana on the NHS after all, after cost regulators changed track and endorsed the drug as a cost effective use of resources.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
